Clinical Trial Update: A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy [Phase 1, Phase 2]

View source ↗

Summary

Praxis Precision Medicines is conducting a Phase 1/2 clinical trial of PRAX-222 in pediatric participants with SCN2A-related developmental and epileptic encepha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Scn2a-related Developmental and Epileptic Encephalopathy

Drugs mentioned

• PRAX-222

Snippet

Sponsor: Praxis Precision Medicines | Conditions: SCN2A-DEE, Epilepsy | Phase 1, Phase 2 | Status: RECRUITING